|
rs28929474
|
|
|
0.010 |
GeneticVariation |
BEFREE |
rs28929474 was significantly enriched in the cholangiocarcinoma group (4.1 vs. 1.7%; OR 2.46, 95% CI 1.14-5.32; Bonferroni corrected p(c) = 0.036), reinforced by Armitage trend testing (OR 2.53; p(c) = 0.032).
|
21138453 |
2011 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
C3435T genotype was an independent predictive factor of good response in breast (response >50 %, i.e., Sataloff T-A and T-B): OR: 4.6 (95 % CI: 1.3-16.1), p = 0.015, for TT patients versus CT and CC patients.
|
23666532 |
2013 |
|
rs7903146
|
|
|
0.010 |
GeneticVariation |
BEFREE |
rs7903146 C>T polymorphism appeared to modulate the risk of MACE: 5-year prevalence was 0.8% in CC patients, 7.2% in CT patients and 9.7% in TT patients (P<.001).
|
28299838 |
2017 |
|
rs2266788
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Also, homozygous risk allele of rs2266788 (CC) significantly associated with risk of MI and UA in patients of chronic stable angina (CSA) patients.
|
29309886 |
2018 |
|
rs4986938
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Also, the ESR2 rs4986938 (38 bp 3' of STP) GG genotype was associated with a higher risk of bile duct cancer (OR = 3.3, 95% CI 1.3-8.7) compared with the AA genotype, although this estimate was based on a small number of subjects.
|
20172949 |
2010 |
|
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRAF inhibitors showed activity in BRAF V600E mutated cholangiocarcinomas and pancreatic carcinomas in non-first line settings.
|
31221175 |
2019 |
|
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRAF inhibitors showed activity in BRAF V600E mutated cholangiocarcinomas and pancreatic carcinomas in non-first line settings.
|
31221175 |
2019 |
|
rs11887534
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Carriers of the CG genotype of ABCG8 rs11887534 had higher risk of biliary stones [odds ratio (OR) = 2.3, 95% confidence interval (CI) 0.82-6.5), gallbladder cancer (OR = 4.3, 95% CI 1.7-10.4) and bile duct cancer (OR = 1.94, 95% CI 0.64-5.91), compared with carriers of the GG genotype.
|
21062971 |
2011 |
|
rs12979860
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.
|
23936821 |
2013 |
|
rs5275
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Differentiation of the type 1 EC is significantly and independently influenced by rs5275 polymorphism. rs5275 CC patients have a lower risk to present a G2-G3 EC.
|
25900875 |
2015 |
|
rs34612342
|
|
|
0.010 |
GeneticVariation |
BEFREE |
DNA from patients with HCC (n=48) or cholangiocarcinoma (n=84) compared to non-cancerous controls (n=308) were genotyped for the Y165C and G382D mutations in MYH.
|
16292541 |
2006 |
|
rs36053993
|
|
|
0.010 |
GeneticVariation |
BEFREE |
DNA from patients with HCC (n=48) or cholangiocarcinoma (n=84) compared to non-cancerous controls (n=308) were genotyped for the Y165C and G382D mutations in MYH.
|
16292541 |
2006 |
|
rs2072671
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For CDA rs2072671 (A>C), AC and CC patients had a lower risk of neutropenia than AA patients (P=0.01, hazard ratio: 0.61, 95% confidence interval: 0.41-0.89).
|
30889042 |
2019 |
|
rs2106261
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Further, neutrophil/lymphocyte (N/L) ratio, C-reactive protein (CRP), and interleukin-6 (IL-6) expression levels were lower in PAF patients with the ZFHX3 SNP rs2106261 minor allele (TT+TC) than in CC patients (N/L ratio: CC 2.22 ± 0.08, TT+TC 1.98 ± 0.06, p = 0.018; CRP: CC 0.103 ± 0.009 mg/dl, TT+TC 0.076 ±0.007 mg/dl, p = 0.016; IL-6: CC 60.3 ± 3.0 pg/ml, TT+TC 52.8 ± 2.3 pg/ml, p = 0.04).
|
30180182 |
2018 |
|
rs3024270
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, decreased risk of invasive bladder cancer was found in carrying rs3024270 CC patients.
|
29595036 |
2019 |
|
rs3769839
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.
|
28779025 |
2018 |
|
rs7731017
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.
|
28779025 |
2018 |
|
rs3197999
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we assessed the primary sclerosing cholangitis-associated variant rs3197999 in the MST1 gene, coding for RON receptor tyrosine kinase ligand macrophage stimulating protein, in a large European cholangiocarcinoma cohort.
|
23422030 |
2013 |
|
rs763569821
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, the frequency of primary liver carcinoma (PLC) with biliary differentiation, such as cholangiocarcinoma (CC) and combined hepatocholangiocarcinoma (CHCC), in GH remains unclear We analyzed the histologic type of 20 PLCs occurring in the background of GH; all patients were homozygotic for the C282Y mutation.
|
11710692 |
2001 |
|
rs2289278
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In children sensitized to certain allergens, a genetic predisposition (rs2289278 genotype CC) significantly increased the risk of AD.
|
26712523 |
2016 |
|
rs9679162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, the G<i>ALNT14</i>-rs9679162 'TT' genotype was associated with perineural invasion and lymph node metastasis, as well as unfavorable overall survival in patients with resected cholangiocarcinoma.
|
28588705 |
2017 |
|
rs12979860
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Levels of ISGs and IFNL2/3 mRNAs were lower in IFNL3 rs12979860 CC patients compared with non-CC patients, and in treatment responders, compared with nonresponders.
|
26020282 |
2016 |
|
rs1003723
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Male and female carriers of the T allele of LDLR IVS9-30C>T (rs1003723) had a 1.5-fold risk of bile duct cancer.
|
18296645 |
2008 |
|
rs4938723
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MiR-34b/c rs4938723 was associated with ESCC TNM staging, differentiation degree, and lymph node metastasis (LNM) for ES CC patients (all P < 0.05).
|
29270777 |
2019 |
|
rs3219476
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma.
|
23138270 |
2013 |